Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.

Abstract

BACKGROUND:

Temozolomide (TMZ) is safe and effective in the treatment of aggressive pituitary adenomas (PAs). However, the optimal duration of TMZ therapy is still unknown. Moreover, data about administration of TMZ in elderly (≥65 years) people to treat aggressive PAs are scarce. We report the case of the oldest female patient undergoing the longest TMZ protocol described so far to treat an aggressive, initially silent corticotroph PA.

CASE REPORT:

The patient initially underwent partial surgical removal of the PA. Subsequent treatment with cabergoline was applied, but it was unsuccessful in controlling the growth of the residual tumor. Pasireotide and external radiation also showed to be ineffective; therefore, treatment with TMZ was started at the standard dose of 200 mg/m2/day for 5 days every 4 weeks for a total of 47 cycles. At the time of treatment's beginning, the patient was 83 years old. Radiological follow-up documented a progressive, remarkable reduction of the adenoma and the last imaging, after 39 cycles of TMZ, showed an intrasellar lesion with large areas of cystic degeneration. The patient also developed adrenal deficiency managed with glucocorticoid replacement. No major side effects were observed throughout the treatment, with exception of nausea, well controlled with anti-emetic medication. TMZ therapy was discontinued after 47 cycles; hormonal and imaging follow-up investigations documented sustained functional and dimensional response.

CONCLUSIONS:

Our case supports the long-term use of TMZ, confirming its safety and efficacy also for elderly patients.

• Authors: Maria Chiara Decaroli, Anna Ansaloni, Maria Laura Monzani, Marco Losa, Elena Zunarelli, Vincenzo Rochira, Bruno Madeo
• Journal: Journal of the Endocrine Society (J Endocr Soc) Vol. 5 Issue 8 Pg. bvab065 (Aug 01 2021) ISSN: 2472-1972 [Electronic] United States
• PMID: 34195524 (Publication Type: Case Reports)
• Copyright: © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.